73 related articles for article (PubMed ID: 19758298)
1. Treating mineral metabolism disorders in patients undergoing long hemodialysis: a search for an optimal strategy.
Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Chazot C
Hemodial Int; 2009 Oct; 13(4):526-32. PubMed ID: 19758298
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
[TBL] [Abstract][Full Text] [Related]
4. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
5. Review of dialysate calcium concentration in hemodialysis.
Toussaint N; Cooney P; Kerr PG
Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
[TBL] [Abstract][Full Text] [Related]
6. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
7. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation.
Jean G; Souberbielle JC; Chazot C
Nephrol Dial Transplant; 2009 Dec; 24(12):3799-805. PubMed ID: 19622574
[TBL] [Abstract][Full Text] [Related]
8. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis.
Toussaint N; Boddington J; Simmonds R; Waldron C; Somerville C; Agar J
Hemodial Int; 2006 Jul; 10(3):280-6. PubMed ID: 16805890
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency and associated factors in hemodialysis patients.
Jean G; Charra B; Chazot C
J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
[TBL] [Abstract][Full Text] [Related]
10. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
13. Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients.
Molina Vila P; Sánchez Pérez P; Garrigós Almerich E; Peris Domingo A
Hemodial Int; 2008 Jan; 12(1):73-9. PubMed ID: 18271845
[TBL] [Abstract][Full Text] [Related]
14. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
[TBL] [Abstract][Full Text] [Related]
16. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R
Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
[TBL] [Abstract][Full Text] [Related]
17. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L
Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
[TBL] [Abstract][Full Text] [Related]
18. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
[TBL] [Abstract][Full Text] [Related]
19. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
Lee CT; Tsai YC; Ng HY; Su Y; Lee WC; Lee LC; Chiou TT; Liao SC; Hsu KT
J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
[TBL] [Abstract][Full Text] [Related]
20. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
